GentleCure, a nonsurgical treatment for common skin cancer, has reached its 150,000th patient — a milestone the company reports as evidence of growing clinical adoption of image-guided radiotherapy as an alternative to surgery for nonmelanoma skin cancer.

The treatment targets what the announcement describes as common skin cancer, principally basal cell carcinoma, the most frequently diagnosed malignancy in the United States. GentleCure delivers image-guided superficial radiotherapy in an office-based setting, allowing dermatologists to treat lesions without excision, Mohs surgery, or reconstructive closure.

The 150,000-patient figure marks cumulative commercial use since the platform's introduction. According to the company, the milestone reflects sustained uptake across dermatology practices rather than a single-study cohort, positioning the technology as an established option in the nonsurgical management of nonmelanoma skin cancer alongside traditional surgical pathways.

For dermatologists, the relevance is practical. Superficial and basal cell carcinomas arising on cosmetically sensitive sites — the nose, ears, eyelids, lips — often carry functional and aesthetic trade-offs when treated surgically. Image-guided radiotherapy offers an outpatient alternative that avoids incisions and wound healing concerns, an advantage the manufacturer emphasizes for patients who are poor surgical candidates or who decline excision.

The milestone lands as dermatology practices continue to broaden in-office treatment offerings beyond surgical suites. Nonsurgical radiotherapy platforms fit that trajectory: they expand the range of lesions a practice can manage without referral, and they give clinicians a tool for shared decision-making when patients weigh surgery against radiation-based approaches.

Company statements frame the 150,000th patient as a validation of both safety experience and real-world use at scale. As with any manufacturer milestone announcement, cumulative treatment counts describe adoption rather than comparative efficacy; dermatologists evaluating the platform will still want to weigh it against surgical standards on a case-by-case basis.

Still, the scale of use signals that nonsurgical radiotherapy has moved from niche to mainstream consideration in nonmelanoma skin cancer care, and further adoption data will help clarify where image-guided treatment fits in treatment guidelines going forward.